Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations

NCT05169437 is registered in ClinicalTrials.gov with Tempus AI as lead sponsor.

NCT NCT05169437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05169437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
Lead sponsor
Tempus AI
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2022
Completion date
August 27, 2024
Enrollment
22 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

breast tumor, colon tumor, malignant, endometrial cancer, esophageal cancer, head and neck cancer, locally advanced solid tumor, lung tumor, melanoma, metastatic cancer, pancreatic cancer, solid tumor, urologic cancer